COMMACK, New York - It is with great privilege that Avery Biomedical Devices, Inc. (ABD) announces the appointment of Abbott Krieger, M.D., F.A.C.S. as Chief Clinical Liaison.
Dr. Krieger’s expertise with Avery breathing pacemakers began in 1981 while he was Chief of Neurological Surgery at the University of Medicine and Dentistry of New Jersey. Based on that initial experience, Dr. Krieger went on to pioneer the reinnervation of the diaphragm through the use of intercostal to phrenic nerve grafts. He reported the first successful use of the technique in Neurosurgery in October, 1994. As a visiting professor, Dr. Krieger has traveled extensively around the world attending grand rounds and assisting other physicians in the development of their local diaphragm pacing programs.
Dr. Krieger most recently served as Clinical Professor in the Department of Neurological Surgery at the USC Keck School of Medicine in Los Angeles. He is currently in private practice in Beverly Hills, CA. As Chief Clinical Liaison, Dr. Krieger will lecture about the indications and latest advances in diaphragm pacing, and be available for clinical discussions regarding potential candidates for the breathing pacemaker.
Linda Towler, CEO, states, “We are honored to have Dr. Krieger join our team. His experience and expertise will be an invaluable addition to the future growth of ABD.”
ABOUT ABD
Avery Biomedical Devices, Inc. (ABD) is a privately-held biomedical device manufacturer located on Long Island, New York. It produces the breathing pacemaker: an implanted phrenic nerve stimulator which is used to free many quadriplegic and central hypoventilation patients from mechanical ventilation. Through its affiliate, Avery Custom Devices, Inc., ABD manufactures high-quality platinum contact electrodes for research projects, clinical trials and commercially distributed medical devices.
ABD is ISO-13485 certified, and an FDA registered manufacturer of Class III medical devices.
Should you know a patient with quadriplegia, central sleep apnea or other condition that may benefit from a breathing pacemaker, or if you are interested in arranging a meeting with Dr. Krieger please contact us.
CONTACT Kenneth R. Aron, V. P. Sales & Marketing +1-631-864-1600 www.averybiomedical.com
Source: Avery Biomedical Devices, Inc.
Kenneth R. Aron, V. P. Sales & Marketing of Avery Biomedical, +1-631-864-1600
Related Press Releases
Abbott to Acquire Solvay Pharmaceuticals BusinessSeptember 27th, 2009 ABBOTT PARK, Illinois -
- Diversifies Abbott's pharmaceutical products, expanding international growth platform
- Supports long-term strategy to bolster presence in key global emerging markets
- Adds substantial R&D spending capacity to accelerate promising pipeline programs
- Establishes Abbott's presence in the growing global vaccines market
- Provides accretion of approximately US$0.10 to ongoing EPS in 2010, accelerating to more than US$0.20 by 2012, increasing thereafter
Abbott today announced a definitive agreement with the Solvay Group for Abbott to acquire Solvay's pharmaceuticals business for EUR 4.5 billion (US$6.6 billion) in cash, providing Abbott with a large and complementary portfolio of pharmaceutical products and a significant presence in key global emerging markets. The acquisition also includes full global rights to the fenofibrate franchise.
Results from Abbott's PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery DiseaseSeptember 23rd, 2009 SAN FRANCISCO -
Abbott (NYSE: ABT) today announced primary results from its groundbreaking PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) clinical trial. PROSPECT is the first prospective natural history study to evaluate the role of vulnerable plaque in unexpected heart attacks and the natural progression of coronary artery disease.
Abbott's XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COMPARE TrialSeptember 22nd, 2009 SAN FRANCISCO -
- Independent Study of 1,800 Patients Affirms Outstanding Performance of XIENCE V vs. TAXUS Liberte
Late-breaking data presented today from the COMPARE trial demonstrated that Abbott's (NYSE: ABT) market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System demonstrated significantly better outcomes in key safety and efficacy measures compared to the TAXUS(R) Liberte Paclitaxel-Eluting Coronary Stent System (TAXUS).
New Avery Dennison Video Demonstrates How Item-Level RFID at American Apparel(R) Helped Achieve 99% Inventory Accuracy and a 14% Sales IncreaseJune 30th, 2009 FRAMINGHAM, Massachusetts -
A new video that guides viewers through the innermost operations of American Apparel's item-level RFID inventory management system can now be accessed by apparel, retail and RFID professionals at www.ibmd.averydennison.com/american-apparel
(Photo: www.newscom.com/cgi-bin/prnh/20090701/PH41122 )
Titled RFID Case Study - American Apparel, the video is the first multimedia production that demonstrates how the largest apparel producer in the U.S. deployed item-level RFID to overcome inventory accuracy and replenishment challenges at selected retail stores, while appreciably increasing sales.
Abbott Receives CE Mark for Company's Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Advancing Leadership PositionJune 22nd, 2009 ABBOTT PARK, Illinois - Broad Size Matrix of XIENCE PRIME to be Launched in Europe in the Third Quarter
Abbott announced today that it has received CE Mark (Conformite Europeenne) for its next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. The company plans to launch XIENCE PRIME in a broad size matrix with lengths up to 38 mm in Europe in the third quarter.
Abbott & BioGenex Extend the Technology Co-development and Distribution Agreement for Marketing the Xmatrx(R) Advanced Staining Platform for the Automation of FISH, IHC and ISH Molecular Diagnostic AssaysJune 1st, 2009 SAN RAMON, California - BioGenex, a developer of innovative instruments and reagents for automated slide based staining systems for molecular diagnostics, announced today that Abbott has entered into a definitive agreement to extend the technology co-development and distribution agreement to market the Xmatrx(R) platform for the automation of Abbott's extensive FISH product line. Under the terms of the agreement Abbott customers will have the option to run IHC and ISH on the Xmatrx and BioGenex customers to run FISH on their system.
Pharma and Biotech Companies Plug into Singapore's Integrated Research NetworkMay 18th, 2009 ATLANTA - Singapore provides a home for innovation in Asia
Leading pharmaceutical and biotech companies are drawing on Singapore's integrated network of public-sector and academic institutes to enhance their R&D productivity, leverage academic insights and diversify risks. Located at the heart of Asia with a population base that is representative of key Asian ethnic groups, Singapore provides a home-base of innovation for companies to test and develop new solutions for Asia and beyond.
Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three YearsMarch 28th, 2009 ORLANDO, Florida - In SPIRIT II Trial, XIENCE V Drug Eluting Stent Demonstrates Clinically
Meaningful Reductions Compared to TAXUS in Key Safety Endpoints, Including an
88 Percent Reduction in the Risk of Cardiac Death at Three Years
Long-term data presented today from Abbott's (NYSE: ABT) SPIRIT II
clinical trial demonstrated that the clinical advantages of the XIENCE V(R)
Everolimus Eluting Coronary Stent System continued to increase between two
and three years compared to the TAXUS(R) Express2(TM) Paclitaxel-Eluting
Coronary Stent System / TAXUS(R) Liberte(TM) Paclitaxel-Eluting Coronary
Stent System (TAXUS). Both TAXUS Express2 (73 percent of lesions) and TAXUS
Liberte (27 percent of lesions) were used as controls in the SPIRIT II trial.
Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical TrialMarch 23rd, 2009 ABBOTT PARK, Illinois - Abbott (NYSE: ABT) today announced the initiation of the next phase of
the ABSORB clinical trial to evaluate the safety and performance of the
company's fully bioabsorbable drug eluting coronary stent. This second phase
of the ABSORB clinical trial will enroll approximately 80 patients at 10
centers in Europe, Australia and New Zealand, and will incorporate device
enhancements designed to improve deliverability and vessel support.
The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting StentMarch 11th, 2009 ABBOTT PARK, Illinois - Data Demonstrate Bioabsorbable Stent Is Absorbed Within Two Years,
Leaving Behind Blood Vessels that Appear to Move and Function Similar to
Untreated Vessels
A comprehensive analysis published today in The Lancet, one of the
world's leading medical journals, from the ABSORB clinical trial demonstrated
that Abbott's bioabsorbable drug eluting stent, currently in development,
successfully treated coronary artery disease and was absorbed into the walls
of treated arteries within two years. The two-year data also demonstrated
that after the bioabsorbable device was absorbed, the treated blood vessels
appeared to move and function similar to unstented arteries.
Related News
MakroCare announces workshop on Advanced GCP on May 15May 6th, 2009 HYDERABAD - MakroCare, a global clinical services firm, provides clinical research support to pharmaceutical, biotechnology, and medical device industries, is taking a lead in the training of professionals for the clinical research industry by providing series of informational through workshop and seminars. Advanced GCP workshop will be held at CHITRAMAYEE Auditorium, State Arts Gallery, Kavuri Hills, Madhapur, Hyderabad on May 15.
SEC settles charges against Avery Dennison in payoffs to foreign officialsJuly 29th, 2009 SEC settles cases against Avery DennisonLOS ANGELES — Adhesive label maker Avery Dennison Corp. on Tuesday settled a case that accused it of promising or making improper payments to foreign officials.
New York Rangers agitator Sean Avery scratched for Game 5 against Washington CapitalsApril 25th, 2009 Rangers' Avery scratched for Game 5 vs. CapitalsWASHINGTON — Sean Avery is being benched for Game 5 of the New York Rangers' first-round playoff series against the Washington Capitals.
Abbott Laboratories pays $130 million to purchase nutrition unit in India, building its marketJuly 28th, 2009 Abbott pays $130 million to expand nutrition unitNORTH CHICAGO, Ill. — Abbott Laboratories said Tuesday it is expanding its nutritional business footprint in India with the $130 million buyout of a Wockhardt Ltd.
Appeals court tosses antitrust claims lodged against Abbott Labs over AIDS drug costJuly 8th, 2009 Appeals court rules for Abbott in AIDS drug caseSAN FRANCISCO — A federal appeals court has rejected a lawsuit accusing Abbott Laboratories of antitrust violations over a sudden 400-percent price hike of a popular AIDS drug. Advocacy groups and drug benefit providers sued Abbott in 2004.
Avery returned to Rangers lineup by suspended coach Tortorella following 1-game benchingApril 26th, 2009 Avery back in Rangers lineup following benchingNEW YORK — Sean Avery is back on the ice for the New York Rangers, and the decision to return him to the lineup Sunday was made by suspended coach John Tortorella. Avery took a pair of senseless penalties that threatened New York's one-goal lead in a Game 4 victory over the Washington Capitals on Wednesday.
First bionic eye to undergo clinical tests by 2011April 28th, 2009 SYDNEY - The first clinical test of a bionic eye is likely within two years and commercialisation within five, according to researchers. A bionic eye is a form of neural prosthesis (artificial extensions of body) intended to partially restore lost vision or amplify existing vision.
Ind. police arrest 2 suspected of crashing wedding, stealing cash-filled cards from newlywedsSeptember 30th, 2009 Suspected wedding crashers arrested in Ind. theftSEYMOUR, Ind.
Belgium's Solvay sells its pharmaceutical business to Abbott Laboratories of US for $7.6 blnSeptember 30th, 2009 Solvay sells pharma division to Abbott for $7.6BBRUSSELS — Solvay, the Belgian chemical and pharmaceutical group, said Monday it has agreed to sell its entire pharmaceutical business to Abbott Laboratories of Abbott Park, Illinois, for euro5.2 billion ($7.6 billion). The American company already holds U.S.
Analyst upgrades shares of Avery Dennison on expectations that investors will start buyingSeptember 11th, 2009 Ahead of the Bell: Avery Dennison shares upgradedNEW YORK — Avery Dennison Corp. is cutting costs, reducing debt and improving cash flow, an analyst said Friday as he upgraded shares of the adhesive label maker and office supplies provider.
